Online Trial Tracker - Larvol Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi

NCT00133367: Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus

Completed

Tacrolimus, Sirolimus, G-CSF, Antithymocyte globulin, Thymoglobulin, Fludarabine, Melphalan

Massachusetts General Hospital, Dana-Farber Cancer Institute

Multiple Myeloma, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Myelogenous Leukemia, Lymphoblastic Leukemia

11/07

11/11

NCT00346359: Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer

Completed

anti-thymocyte globulin, busulfan, fludarabine phosphate, methotrexate, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation

Fred Hutchinson Cancer Center, National Cancer Institute (NCI)

Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases

11/07

NCT00611351: Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

Completed

anti-thymocyte globulin, immunosuppressant, busulfan, Busulfex, Myleran, cyclophosphamide, cytophosphane, mycophenolate mofetil, CellCept, tacrolimus, Protopic, Envarsus XR, Astagraf XL, polymerase chain reaction, polymorphism analysis, flow cytometry, laboratory biomarker analysis, pharmacogenomic studies, pharmacological study, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation

University of Nebraska, National Cancer Institute (NCI)

Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Secondary Myelofibrosis

02/08

09/08

NCT00186628: Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Completed

Total lymphoid irradiation, TLI, Rituximab, Rituxan, Anti-thymoglobulin, rabbit (ATG, rabbit ATG), Cyclosporine, CSP, Sandimmune, Mycophenylate mofetil, MMF, CellCept, Filgrastim, G-CSF, Granulocyte-colony stimulating factor, Neupogen, Granisetron, Sancuso, Solumedrol, Medrol, Depo-Medrol, A-Methapred, Acetaminophen, Tylenol, Diphenhydramine, Benadryl, Hydrocortisone, Westcort

Stanford University, The Leukemia and Lymphoma Society, National Cancer Institute (NCI)

Leukemia, Mast-Cell, Mantle-cell Lymphoma

11/10

12/10

NCT00589563: Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

Completed

anti-thymocyte globulin, cyclophosphamide, etoposide, fludarabine phosphate, melphalan, methotrexate, sirolimus, tacrolimus, allogeneic hematopoietic stem cell transplantation, hematopoietic stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation

City of Hope Medical Center, National Cancer Institute (NCI)

Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition, Secondary Myelofibrosis, Small Intestine Cancer

02/12

NCT00343785: Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant

Completed

cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, anti-thymocyte globulin, ATG, ATGAM, lymphocyte immune globulin, Thymoglobulin, cyclosporine, ciclosporin, cyclosporin, cyclosporin A, CYSP, Sandimmune, allogeneic bone marrow transplantation, bone marrow therapy, allogeneic, bone marrow therapy, allogenic, transplantation, allogeneic bone marrow, transplantation, allogenic bone marrow, methotrexate, amethopterin, Folex, methylaminopterin, Mexate, MTX, DNA analysis, flow cytometry, polymorphism analysis, laboratory biomarker analysis

Fred Hutchinson Cancer Center, National Heart, Lung, and Blood Institute (NHLBI)

Aplastic Anemia

05/12

08/12

NCT01044745: Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

Terminated

rituximab, IDEC-C2B8, IDEC-C2B8 monoclonal antibody, Mabthera, MOAB IDEC-C2B8, Rituxan, mycophenolate mofetil, Cellcept, MMF, tacrolimus, FK 506, Prograf, anti-thymocyte globulin, ATG, ATGAM, lymphocyte immune globulin, Thymoglobulin, allogeneic hematopoietic stem cell transplantation, laboratory biomarker analysis, graft versus host disease prophylaxis/therapy, prophylaxis/therapy, graft versus host disease, prophylaxis/therapy, GVHD, cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, fludarabine phosphate, 2-F-ara-AMP, Beneflur, Fludara, busulfan, BSF, BU, Misulfan, Mitosan, Myeloleukon, total-body irradiation, TBI, graft-versus-tumor induction therapy, graft versus host disease induction, graft versus tumor induction, immunosuppressive therapy, immunosuppression

University of Nebraska, National Cancer Institute (NCI)

Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Blastic Phase Chronic Myelogenous Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Graft Versus Host Disease, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Adult T-cell Leukemia/Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage I Small Lymphocytic Lymphoma, Stage II Adult T-cell Leukemia/Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia, Waldenström Macroglobulinemia

12/12

10/17

NCT01116232: Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

Terminated

anti-thymocyte globulin, rituximab, Rituxan®, sirolimus, Rapamune®, tacrolimus, Prograf, laboratory biomarker analysis, allogeneic hematopoietic stem cell transplantation, management of therapy complications, peripheral blood stem cell transplantation

Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)

Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms

05/13

06/13

NCT01246206: Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT

Completed

Tacrolimus and Thymoglobulin, PROGRAF®

Barbara Ann Karmanos Cancer Institute

Hematological Malignancies

10/13

NCT00720629: Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

Terminated

Visilizumab, Tacrolimus, Methotrexate, Antithymocyte globulin (ATG), Thymoglobulin-ATG

H. Lee Moffitt Cancer Center and Research Institute, National Institutes of Health (NIH), National Cancer Institute (NCI)

Graft Versus Host Disease

12/13

NCT00691015: Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Completed

rituximab, Rituxan, MabThera, Zytux, busulfan, Busulfex, Myleran, carmustine, Bicnu, Gliadel, cyclophosphamide, Cytoxan, Cytoxan Lyophilized, Neosar, cytarabine, Depocyt, etoposide, Etopophos, Toposar, fludarabine phosphate, Fludara®, melphalan, Alkeran, total body irradiation (TBI), radiotherapy, anti-thymocyte globulin IV, Thymoglobulin

Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)

Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms

04/14

NCT01390402: Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG

Completed

Fludarabine, Fludarabine Phosphate, Fludara, Busulfan, Busulfex, Myleran, NK cell infusion:, Interleukin-2, IL-2, Aldesleukin, Proleukin, Anti-Thymocyte Globulin, ATG, Thymoglobulin, Allogeneic related Stem Cell Transplant, Tacrolimus, Prograf, Methotrexate, G-CSF, Filgrastim, Neupogen

M.D. Anderson Cancer Center, National Cancer Institute (NCI)

Leukemia, Chronic Myelogenous Leukemia

11/14

NCT02877082: Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients

Terminated

Thymoglobulin, Antithymocyte Globulin, Antithymocyte Serum, ATG, ATGAM, ATS, Anti-Thymocyte Globulin, Bortezomib, LDP 341, MLN341, PS-341, PS341, Velcade, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic

Emory University

Acute Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Graft Versus Host Disease, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Small Lymphocytic Lymphoma

07/17

NCT00054340: Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder

Completed

1/2

anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, methotrexate, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation

Fred Hutchinson Cancer Center, National Cancer Institute (NCI)

Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases

09/06

NCT00409695: Thymoglobulin (ATG) Dose Finding Study

Terminated

1/2

Low Dose Thymoglobulin (ATG), ATG, Antithymocyte Globulin, High Dose Thymoglobulin (ATG)

M.D. Anderson Cancer Center, Genzyme, a Sanofi Company

Graft vs Host Disease

08/07



	Diseases Companies Products Productz Mechanisms of Action Sites